ZL-1310 earns fast track designation in extensive-stage small cell lung cancer after early trial data showed tumor shrinkage ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Health Canada has granted a Notice of Compliance with conditions (NOC/c) for Tagrisso® (osimertinib) for the treatment of patients with locally advanced, unresectable (stage III) non-small cell lung ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

BeiGene has announced that its Tevimbra (tislelizumab) has been approved by the European Commission (EC) as part of a ...

Higher-than-usual doses of radiation in the treatment of inoperable lung cancer can be safely combined with immunotherapy ...

Investigators are using MET immunohistochemistry testing and FDA-approved profiling tools to personalize care and address unmet needs in NSCLC treatment.

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment ...

Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET ...

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...